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SUMMARY

Epileptologist Dr.
King-Stephens is
director of clinical
neurophysiology at
Sutter Pacific’s
Epilepsy Program.

Objective: Patients with suspected mesial temporal lobe (MTL) epilepsy typically
undergo inpatient video–electroencephalography (EEG) monitoring with scalp and/or
intracranial electrodes for 1 to 2 weeks to localize and lateralize the seizure focus or
foci. Chronic ambulatory electrocorticography (ECoG) in patients with MTL epilepsy
may provide additional information about seizure lateralization. This analysis
describes data obtained from chronic ambulatory ECoG in patients with suspected
bilateral MTL epilepsy in order to assess the time required to determine the seizure
lateralization and whether this information could influence treatment decisions.
Methods: Ambulatory ECoG was reviewed in patients with suspected bilateral MTL
epilepsy who were among a larger cohort with intractable epilepsy participating in a
randomized controlled trial of responsive neurostimulation. Subjects were implanted
with bilateral MTL leads and a cranially implanted neurostimulator programmed to
detect abnormal interictal and ictal ECoG activity. ECoG data stored by the neurostimulator were reviewed to determine the lateralization of electrographic seizures and
the interval of time until independent bilateral MTL electrographic seizures were
recorded.
Results: Eighty-two subjects were implanted with bilateral MTL leads and followed for
4.7 years on average (median 4.9 years). Independent bilateral MTL electrographic
seizures were recorded in 84%. The average time to record bilateral electrographic
seizures in the ambulatory setting was 41.6 days (median 13 days, range 0–376 days).
Sixteen percent had only unilateral electrographic seizures after an average of
4.6 years of recording.
Significance: About one third of the subjects implanted with bilateral MTL electrodes
required >1 month of chronic ambulatory ECoG before the first contralateral MTL
electrographic seizure was recorded. Some patients with suspected bilateral MTL seizures had only unilateral electrographic seizures. Chronic ambulatory ECoG in
patients with suspected bilateral MTL seizures provides data in a naturalistic setting,
may complement data from inpatient video-EEG monitoring, and can contribute to
treatment decisions.
KEY WORDS: EEG monitoring, Electrocorticography, Ambulatory EEG, Intracranial
EEG, Responsive stimulation, Localization.
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Key Points
•
•
•
•

Ambulatory electrocorticograms were obtained in
patients implanted with a responsive neurostimulator
and bilateral mesial temporal intracranial electrodes.
In patients with bilateral seizures, the average time to
record bilateral electrographic seizures in the ambulatory setting was 41.6 days (median 13, range 0–376).
Some patients suspected to have bilateral MTL seizures after standard diagnostic localization evaluations had only unilateral electrographic seizures.
Chronic ambulatory ECoG samples provide naturalistic data that complement inpatient monitoring, and
may contribute information that affects treatment
decisions.

Mesial temporal lobe (MTL) epilepsy is the most common surgically remediable form of epilepsy.1 Patients with
MTL epilepsy being considered for resective surgery typically undergo inpatient video–electroencephalography
(EEG) monitoring with scalp and sometimes intracranial
electrodes to establish localization and lateralization of the
seizure focus or foci. The duration of video-EEG monitoring varies but is usually <2 weeks. The literature suggests
that for some patients, this period of monitoring may not be
sufficient to establish whether the MTL seizure onsets are
unilateral or bilateral, and, in patients with bilateral onset,
to establish the relative distribution of left- and right-sided
seizures.2–4
Electrocorticography (ECoG) samples were examined in
patients with medically intractable partial seizures who
were suspected to have bilateral MTL seizure onsets after
standard localization testing, and were chronically
implanted with bilateral MTL electrodes. The intent was to

assess the time required to confidently determine the laterality of electrographic seizures in a naturalistic setting and to
determine whether this information could influence treatment recommendations.

Methods
Ambulatory ECoG was analyzed retrospectively in subjects who were implanted with bilateral MTL electrodes
while participating in a double-blind, randomized, shamstimulation controlled investigational trial of the RNS System (NeuroPace, Inc., Mountain View, CA, U.S.A.) as an
adjunctive treatment for adults with medically intractable
partial-onset seizures from one or two foci.5 Subjects were
18 years of age or older with partial-onset seizures that were
intractable to two or more antiepileptic medications and
who had seizures arising from one or two foci, as identified
by standard localization procedures at that center. After a 3month baseline, subjects were implanted with the neurostimulator and leads. The neurostimulator was programmed in
every subject to detect and store specific ECoG patterns
identified by the physician, including electrographic seizures. One month after implantation, subjects were randomized 1:1 to receive responsive or sham stimulation for
4 months. After the completion of the fifth postimplantation
month, all subjects entered an open-label period during
which every subject received responsive stimulation. The
open-label period was complete 2 years after implantation,
after which subjects transitioned into a long-term treatment
trial to provide an additional 7 years of prospective followup. The methodology, patient selection criteria, and results
of the randomized controlled study and interim results of
the ongoing long-term treatment study have been published
previously.5–7
The RNS System provides responsive cortical stimulation via a cranially implanted programmable neurostimu-
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lator connected to recording and stimulating depth and/or
subdural cortical strip leads that are surgically placed at
the seizure focus. Each lead contains four electrode contacts, and up to two leads can be connected to the neurostimulator. The neurostimulator continuously senses
ECoG activity through the electrodes and is programmed
by the physician to detect specific patterns in the ECoG,
such as patterns characteristic of the onset of an electrographic seizure, and to provide brief pulses of stimulation in response to the detected patterns. In usual clinical
use, detection is optimized and then responsive stimulation is enabled.
Each ECoG sample stored by the neurostimulator is typically 90 s (60 s before detection and 30 s after). If the neurostimulator’s 6-min storage capacity is filled, then the
earliest sample may be overwritten by the newest. To free
neurostimulator memory, patients use a handheld wireless
wand at home to transfer data from the neurostimulator to a
remote monitor, and then intermittently transmit the data
securely through the internet to a secure centralized database for storage. The physician reviews these ECoG samples via a programmer in the office or remotely using a
secure web browser.
ECoG recordings were reviewed by two independent
reviewers. Electrographic seizures were defined as episodes
of low-voltage fast activity or rhythmic sharp activity, distinct from background, evolving and lasting longer than
25 s. This definition of electrographic seizure was derived
empirically, since this ensured that a clear onset and frequency evolution could be observed within the ECoG sample. In addition, the literature suggests that mesial temporal
onset seizures with clinical symptoms will exceed this duration and that electrographic seizures that are clinically silent
will be shorter.8,9
To determine seizure lateralization and the interval of
time until independent bilateral MTL seizure onsets were
recorded, ECoG data were reviewed from implant until at
least one electrographic seizure was recorded from each
side. For subjects in whom only unilateral seizures were
recorded, all ECoG recordings were reviewed from implant
to the data cut-off date (6/13/2013).

Results
Eighty-two of the 191 subjects who participated in the
randomized controlled study were implanted with bilateral
MTL electrodes (Fig. S1). The average follow-up for these
subjects was 4.7 years (median 4.9 years; range 1.2 months
to 7.1 years). During the first year after implantation, subjects transferred neurostimulator data to the remote monitor
once per day on average (ranging from an average of 2.2
times a day to once every 3.7 days). This provided an average of 2.5 ECoG recordings per day (range 0.8–7.6) for
physician review. An example of ECoG recordings obtained

by the neurostimulator and viewed using the RNS System is
provided in Figure 1.
Demographics for the 82 subjects implanted with bilateral MTL leads are presented in Table 1. Based on preimplantation diagnostic localization procedures, which
included video-EEG monitoring in all subjects, 71 of these
82 subjects were presumed to have bilateral seizures at the
time of implantation of the RNS System. The remaining 11
subjects were presumed to have unilateral seizures; however, bilateral MTL leads were implanted because other
diagnostic localization testing suggested contralateral MTL
structural or functional abnormalities. These included bilateral hippocampal atrophy or mesial temporal sclerosis
(three subjects), an intracarotid amobarbital (Wada) test
indicating that the contralateral temporal lobe did not adequately support memory (five subjects), a prior contralateral
temporal lobectomy (two subjects), or discordant EEG and
positron emission tomography (PET) lateralization (one
subject). No subject in this series had diagnostic localization
testing that was entirely concordant for unilateral MTL
epilepsy.
The most common lead implant strategy was to place
depth leads along the long axis of the hippocampus. Ninetysix percent (79/82) of the subjects were implanted with a
depth lead in each hippocampus, and 4% (3/82) were
implanted with bilateral subtemporal cortical strip leads.
Six of the 82 subjects had already undergone a temporal
lobectomy, but leads were placed in residual MTL tissue.
Examples of cortical strip lead and hippocampal depth lead
implantations, as well as an example of a depth lead implantation in a subject with a prior temporal lobectomy are provided in Figure 2.
The first analysis considered all 82 subjects. Thirteen
(16%) of the 82 subjects had only unilateral electrographic
seizures after an average of 4.6 years of ambulatory ECoG
recording (Table 2). Sixty-nine (84%) of 82 ultimately had
bilateral MTL electrographic seizures with an average time
to record the first contralateral electrographic seizure of
41.6 days (median 13 days; range 0–376 days). The first
contralateral electrographic seizure was recorded within the
first postimplantation month in 68% (47/69), which was
before randomization and therefore before any subject
was treated with responsive stimulation. Thirty-two percent
(22/69) of the subjects had the first contralateral electrographic seizure after the fourth week, which was when one
half of the subjects were randomized to receive responsive
stimulation. In these 22 subjects, there was no difference
between those randomized to receive responsive stimulation
(N = 11) and those in the group who did not receive responsive stimulation (sham stimulation group, N = 11) in the
time to record the first contralateral seizure (p = 0.51, twosample t-test). Figure 3 illustrates the length of time before
independent bilateral MTL electrographic seizures were
recorded.
Epilepsia, **(*):1–9, 2015
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B

Figure 1.
Examples of bilateral seizure onsets recorded in one subject. Panels A and B show left- and right- sided seizure onsets (respectively)
recorded in the same subject. In Panel A, the onset in the left hippocampus begins with spiking followed by high amplitude fast activity on
channel 1. The flag labeled “B1″ on the first channel at 89.8 s denotes detection of abnormal electrographic activity by the neurostimulator based on the programmed detection settings. The flags labeled “Tr” at 90 s indicate delivery of responsive stimulation. There is an
artifact in the recording when responsive stimulation is delivered. In Panel B, the onset in the right hippocampus begins with rhythmic beta
activity on channel 3. The flag labeled “B2” on the third channel at 105.3 s denotes detection of abnormal electrographic activity by
the neurostimulator based on the programmed detection settings. The flags labeled “Tr” at 105.5 s indicate delivery of responsive
stimulation.
Epilepsia ILAE

The next analysis considered the 71 subjects who were
presumed to have independent bilateral seizure onsets based
on preimplantation diagnostic localization procedures. Nine
of these 71 subjects had only unilateral electrographic seizures by chronic ambulatory ECoG after an average followup of 5.0 years (median 4.8 years; range 2.9–6.5 years).
Bilateral electrographic MTL seizures were recorded by
ambulatory ECoG in 62 (87%) of the 71 subjects. The first
contralateral seizure was obtained during the first week of
ambulatory ECoG in 38.7% (24/62), during the second
week in 17.7% (11/62), during the third week in 6.5%
(4/62), during the fourth week in 9.7% (6/62), and after the
fourth week in 27.4% (17/62).
Eleven of the 82 subjects were thought to most likely
have unilateral seizures based on the preimplantation diagnostic localization, although all of these subjects had localization testing that suggested that there were contralateral
MTL abnormalities. Two of these subjects had already had
a temporal lobectomy, and inpatient seizure onsets were
Epilepsia, **(*):1–9, 2015
doi: 10.1111/epi.13010

ipsilateral to the side of resection. With chronic ambulatory
ECoG, 7 (64%) of these 11 subjects had independent bilateral electrographic MTL seizures, with an average time of
72.4 days (median 35 days; range 7–330 days) to record
the first contralateral electrographic seizure. Four of the 11
subjects had only unilateral seizures recorded by chronic
ambulatory ECoG, with an average duration of 3.9 years
(median 4.1 years; range 0.4–7.0 years) of recording.
Lateralization results by ambulatory ECoG were assessed
in subjects according to whether they had undergone a temporal lobe resection. Six of the 82 subjects had already had a
temporal lobectomy. Lateralization by preimplantation
diagnostic localization testing and chronic bilateral ECoG
recording was concordant in two of these patients (bilateral
onsets). Two of the six were presumed to have unilateral seizures prior to implantation but had bilateral electrographic
seizures recorded during chronic ambulatory ECoG, and
two subjects were presumed to have bilateral seizures prior
to implantation but had only unilateral seizures recorded
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Table 1. Demographic and clinical characteristics of
subjects implanted with bilateral mesial temporal
electrodes (N = 82)
Female
Age in yearsa (mean, SD, range)
Duration of epilepsy in yearsa
(mean, SD, range)
Number of AEDs at enrollmenta
(mean, SD, range)
Preimplantb seizure frequency per
month (mean, SD, range)
Prior intracranial monitoring
Prior epilepsy surgery
Prior VNS
Hippocampal atrophy or mesial
temporal sclerosis
Unilateral
Bilateral
Preimplant electrographic seizuresb
Bilateral
Unilateral
Left
Right

47.6% (39/82)
37.2  10.9 (18–60)
19.9  13.2 (2–57)
2.7  1.1 (1–5)
13.7  17.4 (3.0–88.3)
median = 7.0
42.7% (35/82)
7.3% (6/82)
26.8% (22/82)
63.4% (52/82)
34.6% (18/52)
65.4% (34/52)
86.6% (71/82)
13.4% (11/82)
63.6% (7/11)
36.4% (4/11)

a

At time of enrollment into the pivotal study.
Preimplant refers to evaluation prior to implantation of the RNS Neurostimulator and NeuroPace leads.
b

Figure 2.
CT/MRI co-registered images of
hippocampal lead implants. Panels A,
B, and D show pre-implant MRI
images co-registered with postimplant CT images. Panel A is an axial
slice along the axis of the
hippocampus showing the depth
leads implanted bilaterally in the
hippocampi. Panel B shows a sagittal
image of the same implant, where the
cross-hairs identify the second
electrode of the depth lead implanted
in the left hippocampus. Panel C
shows a CT image of the
neurostimulator (implanted in the
parietal skull) connected to bilateral
sub-temporal cortical strip leads.
Panel D shows a coronal image of a
depth lead implanted in the left
hippocampus after a left temporal
resection.
Epilepsia ILAE

with chronic ambulatory ECoG (contralateral to the resection in both subjects). The average duration of time to the
first contralateral seizure in the four post lobectomy subjects
with bilateral onsets was 100 days (median 34.5 days;
range 1–330 days).
Seventy-six of the 82 subjects had not had a temporal
lobectomy and 65 of these 76 subjects had bilateral electrographic seizures recorded by ambulatory ECoG. The duration of time before a contralateral seizure was recorded was
on average 38 days (median 11 days; range 0–376 days).
Demographic and clinical characteristics were compared
between those subjects who ultimately had bilateral independent MTL electrographic seizures and those whose seizures remained strictly unilateral. There was no difference
between the two groups in duration of epilepsy, seizure frequency, number of AEDs, frequency of mesial temporal
sclerosis (MTS) or hippocampal atrophy, or history of treatment with epilepsy surgery or with vagus nerve stimulation
(VNS) (Table S1).
An analysis was performed to assess whether abnormalities on magnetic resonance imaging (MRI) were likely to
predict whether electrographic seizure onsets recorded by
chronic ambulatory ECoG would be unilateral or bilateral,
and whether MRI findings predicted the time until bilateral

A

B

C

D
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Table 2. Lateralization of electrographic seizures by
inpatient EEG and by chronic ambulatory
electrocorticography (ECoG) N = 82
Electrographic seizure onset by
chronic ambulatory ECoG

Electrographic seizure
onsets by inpatient EEG
monitoring

Bilateral (n = 69)

Unilateral (n = 13)

Bilateral (n = 71)
Unilateral (n = 11)

75.6% (n = 62)
8.5% (n = 7)

11.0% (n = 9)
4.9% (n = 4)

electrographic seizures were recorded. Those with bilateral
MTS and/or atrophy were more likely to have independent
bilateral MTL electrographic seizures, whereas those with
unilateral MTS or atrophy were more likely to have unilateral electrographic seizures (p = 0.03, Fisher’s exact test;
Table S2). MRI findings of MTS and/or atrophy did not
predict whether the first contralateral seizure was recorded
within the first 2 weeks (n = 37) or after the first 2 weeks
(n = 32; p = 0.34, Fisher’s exact test), although there was a
trend for subjects with earlier bilateral seizures to have bilateral MTS and/or atrophy (54.1% vs. 31.3%, p = 0.09, Fisher’s exact test).
Another variable that could predict whether the lateralization obtained by chronic ambulatory ECoG differed from
the preimplantation lateralization was whether the subject
had previously undergone inpatient video-EEG monitoring
with intracranial electrodes. Thirty-five subjects had undergone inpatient intracranial monitoring prior to implantation
of the RNS System; 34 were thought to have bilateral seizures, and one to have unilateral seizures. The determination regarding lateralization of MTL seizures changed in
three subjects after chronic ambulatory ECoG (8.6%).
These three subjects were presumed to have bilateral
onsets but had only unilateral MTL electrographic seizures

during chronic ambulatory ECoG (Table S3). The first
bilateral electrographic seizure In the 31 subjects with
bilateral onsets occurred within 1 week in 35.5% (11/31),
during the second week in 19.4% (6/31), during the third
week in 6.5% (2/31), during the fourth week in 9.7% (3/
31), and after 2 weeks in 29.0% (9/31).
Forty-seven subjects had not undergone intracranial monitoring prior to implantation of the RNS System; 37 were
considered to have bilateral MTL onsets and 10 were considered unilateral. The conclusion about lateralization changed in 13 of these subjects after chronic ambulatory ECoG
(27.7%). Six subjects originally categorized as bilateral had
only unilateral electrographic seizures, and seven originally
categorized as unilateral had bilateral electrographic
seizures (Table S4). In the 38 subjects with bilateral electrographic seizures during chronic ambulatory ECoG, the first
contralateral seizure was obtained within 1 week in 36.8%
(14/38), during the second week in 15.8% (6/38), during the
third week in 5.3% (2/38), during the fourth week in 7.9%
(3/38), and after 4 weeks in 34.2% (13/38).
To assess whether the frequency of ECoG recordings influenced the time to record the first contralateral seizure, an
analysis was conducted of the four subjects whose baseline
seizure rate was higher than their average ECoG storage rate
since seizure recordings in these subjects could potentially be
overwritten and not available for review. All of these subjects
had independent bilateral seizures recorded within the first
20 days after implantation, indicating that the overall results
are unlikely to reflect less-frequent sampling in those with
longer latencies to the first contralateral seizure.
The additional data obtained from chronic ambulatory
ECoG led to a temporal lobe resection in three patients who
were not previously thought to be surgery candidates. Each
was believed to have bilateral MTL onsets based on inpatient monitoring and other diagnostic localization testing.

Figure 3.
Time to record bilateral temporal
onsets.
Epilepsia ILAE
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One subject had only unilateral MTL electrographic seizures after 4.4 years of chronic ambulatory ECoG. This
subject had a unilateral temporal lobectomy and continued
to have seizures after the initial resective procedure, but
then became seizure free after a second procedure
21 months later. Another subject had only unilateral MTL
electrographic seizures recorded for 1 year before the first
contralateral MTL electrographic seizure was recorded.
This subject had a unilateral temporal lobectomy 2 years
after the implant and continued to be seizure free 3 years
postresection. The third subject had bilateral MTL electrographic seizures recorded within the first month after
implantation but based on the distribution of seizures was
felt to be a candidate for a palliative nondominant temporal
lobectomy. This surgery was performed 1 year after
implantation and achieved a 63% reduction in seizure frequency. In each of these cases, the neurostimulator and at
least one lead were left in place to sense and record the
ECoG and to provide responsive stimulation in the remaining hippocampus.

Discussion
Patients with MTL epilepsy who are being considered for
an epilepsy resective surgery undergo inpatient video-EEG
monitoring with scalp and/or intracranial electrodes as well
as neuroimaging and functional tests to establish localization and lateralization of the seizure focus or foci. The considerable hospital resources required for scalp and
intracranial video-EEG monitoring and the risk for infection
with prolonged intracranial monitoring usually limit the
duration of monitoring to 1 to 2 weeks. The literature suggests that for some patients with MTL onsets, this period of
monitoring may not be sufficient to definitively establish
whether the seizure onset is unilateral or bilateral, and, in
patients with bilateral onsets, to establish the relative distribution of seizures across left and right.2–4 In addition, seizures recorded after electrode implantation7 or with acute
medication withdrawal10–12 may not be clinically or electrographically typical for that patient.
The ability to monitor intracranial EEG on an ambulatory
basis offers the opportunity to record that patient’s typical
seizures in a naturalistic setting over an extended period and
without reducing antiepileptic medications. In the patients
in this series who were demonstrated by chronic ambulatory
ECoG to have independent bilateral MTL electrographic
seizure onsets, the average time to document the first contralateral seizure was >5 weeks, with a range of days to
many months. Ambulatory ECoG was clinically useful: the
electrographic seizure lateralization changed from the preimplantation lateralization in nearly 20% of subjects, and
some subjects were identified as candidates for temporal
lobectomy.
In some instances, chronic ambulatory ECoG provided
lateralization data that contradicted lateralization made by

preimplantation diagnostic localization procedures. Seven
of 11 patients were presumed to have unilateral seizures
but ultimately had bilateral electrocorticographic seizures
recorded by chronic ambulatory ECoG. Nine of 71 subjects
who were presumed to have bilateral seizures had only unilateral electrographic seizures after years of ambulatory
ECoG. Three subjects were identified as candidates for resective surgery based on the chronic ambulatory ECoG
recordings.
Data from chronic ambulatory ECoG may complement
but cannot substitute for inpatient monitoring with scalp
and/or intracranial electrodes. First, the ambulatory ECoG
data does not indicate whether a clinical seizure has
occurred. Second, spatial sampling is limited to a few electrodes rather than the extensive electrode arrays possible in
the inpatient setting. The chronically implanted electrodes
are placed near the seizure onset in order to detect the electrographic seizure, which requires that standard inpatient
scalp and/or intracranial monitoring be performed to plan
lead electrode locations. In addition, the ECoG storage
capacity of the neurostimulator is limited and, unlike inpatient monitoring, not all electrographic seizures are necessarily stored. If all ECoG samples are not stored, it may take
longer to establish that there are bilateral electrographic seizures. However, there was no evidence to suggest that the
latency to the first contralateral seizure was related to the
rate at which subjects transferred ECoG data for storage.
A potential confound in this data set is that detection settings were modified during the trial as necessary to improve
the detection specificity, and this could have impacted the
ability to record electrographic seizures, as different detection settings will influence what type of ECoG activity is
stored by the neurostimulator. However, detection settings
were initially programmed to be highly sensitive to the types
of ECoG patterns characteristic of electrographic seizures
and were subsequently adjusted to be more sensitive to that
patient’s specific ictal-onset patterns. Thus, it is unlikely
that ECoG recordings containing electrographic seizures
would not be detected and stored.
Although there was no standard protocol for evaluating
and localizing seizure foci, the physicians participating in
this study were highly experienced in procedures to localize
seizure foci and were able to select the type of lead and lead
location. Depth leads were most commonly used and were
usually placed along the length of the hippocampus. Cortical strip leads were less commonly used. It is possible that
one implant strategy could be better able to capture seizures
than another, but there is not sufficient data from this series
to determine the relative merits.
It is unlikely that responsive stimulation therapy or
changes in antiepileptic medications affected the determination of laterality. Responsive stimulation was not enabled in
any of the subjects in the first month after implant, which is
when the majority (68%) of the bilateral onsets were captured. After the first month, there was no difference in the
Epilepsia, **(*):1–9, 2015
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time to detection of the first contralateral electrographic seizure between those randomized to receive responsive stimulation and those who were not. Similarly, antiepileptic
medications were held constant during the first 5 months
after implant (per the study protocol), during which 93% of
the bilateral onsets were captured.
Patients with medically intractable epilepsy of mesial
temporal onset who are candidates for potentially curative
mesial temporal lobe resection can be reliably identified
with inpatient video-EEG monitoring and MRI, supplemented as needed with tests of MTL function such as PET
and neuropsychological and intracarotid testing.
Patients for whom there is consistent localization to one
temporal lobe in aggregate and for whom there are not concerns for significant memory or language deficits after
resection, have a high probability of becoming seizure free
after a temporal lobectomy. One-year and 2-year seizure
remission can be achieved in at least 65% of patients with
unilateral mesial temporal lobe seizure onsets after a temporal lobectomy.13 However, seizure remission is not achieved
or sustained in all patients. Patients who have experienced
two seizure-free years after temporal lobectomy have a
relapse rate, on average, of 3.25% each year,14 with 60% of
patients having at least one recurrence in the first
10 years.15 Lack of a sustained seizure remission could be
caused by residual epileptogenic cortex, including a contralateral mesial temporal seizure focus. This hypothesis is
supported by the risk factors that predict persistent seizures
after a unilateral anterior temporal lobectomy, which
include bilateral temporal lobe epileptiform abnormalities,
structural or functional imaging that show either no abnormalities or bilateral or contralateral abnormalities, and neuropsychological testing and/or intracarotid amobarbital
(Wada) testing indicating contralateral memory abnormalities.14 These findings could indicate that the patient has
independent bilateral MTL onsets.16,17 This may be a common clinical scenario; postmortem neuropathologic studies
describe bilateral mesial temporal sclerosis (MTS) in up to
80% of patients with MTL epilepsy.18–20
Demographics and clinical characteristics such as duration and frequency of seizures and treatment history did not
differentiate subjects for whom chronic ambulatory ECoG
monitoring provided information that contradicted lateralization using inpatient EEG monitoring from patients with
consistent lateralization. The only exception appeared to be
related to whether the subject had undergone inpatient intracranial monitoring. Lateralization changed after chronic
ambulatory ECoG in 8.6% of those subjects who had been
evaluated with inpatient intracranial monitoring (all presumed to be bilateral with inpatient monitoring but determined to be unilateral in the ambulatory setting) and in
27.6% of those patients who did not have inpatient intracranial monitoring (lateralization changing equally between
bilateral and unilateral). The time to record the first MTL
electrographic seizure during chronic ambulatory ECoG
Epilepsia, **(*):1–9, 2015
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monitoring was not different; about 30% required >4 weeks
before the first contralateral electrographic seizure was
recorded.
Patients such as the subjects in this analysis who display
bilateral independent MTL seizures during inpatient monitoring with scalp and/or EEG monitoring and those who
have unilateral seizure onsets with other localization findings that are discordant and/or suggestive of memory or language deficits after surgery may not be good candidates for
a resective surgery. This series suggests that chronic ambulatory ECoG may provide additional information to help
define treatment options.
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